Industry Update: Pharmaceuticals
VRC is proud to release its latest industry report. The report provides a concise, insightful update on the Pharmaceutical industry including recent transactions, market multiples, company performance and purchase price allocation percentages.
Industry Highlights
- On June 15, 2021, PharmaSGP GmbH, a subsidiary of PharmaSGP Holding SE, signed an agreement to acquire a product portfolio with four established OTC brands (Baldriparan, Formigran, Spalt, and Kamol) with the GlaxoSmithKline Group – a leading multinational pharmaceutical group. The agreed purchase price of this transaction is roughly EUR 80M.
- On April 28, 2021, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, completed the acquisition of Amplyx Pharmaceuticals, Inc., who specializes in the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. The acquisition will help to advance its expertise in infectious disease and expand its anti-infectives pipeline.
- On April 9, 2021, Sanofi, a multinational pharmaceutical company, completed the acquisition of Tidal Therapeutics, a pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones.
